European Union - English - EMA (European Medicines Agency)

sanofi winthrop industrie - sarilumab - arthritis, rheumatoid - immunosuppressants - kevzara in combination with methotrexate (mtx) is indicated for the treatment of moderately to severely active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). kevzara can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate.

Canada - English - Health Canada

janssen inc - ustekinumab - solution - 45mg - ustekinumab 45mg - misc. skin and mucous membrane agents

Canada - English - Health Canada

janssen inc - ustekinumab - solution - 90mg - ustekinumab 90mg - misc. skin and mucous membrane agents

Canada - English - Health Canada

novartis pharmaceuticals canada inc - canakinumab - powder for solution - 150mg - canakinumab 150mg - immunosuppressive agents

Canada - English - Health Canada

hoffmann-la roche limited - tocilizumab - solution - 80mg - tocilizumab 80mg - disease-modifying antirheumatic agents

Canada - English - Health Canada

hoffmann-la roche limited - tocilizumab - solution - 200mg - tocilizumab 200mg - disease-modifying antirheumatic agents

Canada - English - Health Canada

hoffmann-la roche limited - tocilizumab - solution - 400mg - tocilizumab 400mg - disease-modifying antirheumatic agents

Canada - English - Health Canada

hoffmann-la roche limited - tocilizumab - solution - 162mg - tocilizumab 162mg - disease-modifying antirheumatic agents

Canada - English - Health Canada

eli lilly canada inc - ixekizumab - solution - 80mg - ixekizumab 80mg - misc. skin and mucous membrane agents

Canada - English - Health Canada

eli lilly canada inc - ixekizumab - solution - 80mg - ixekizumab 80mg - misc. skin and mucous membrane agents